Nanomerics

Nanomerics is an award-winning, clinical-stage biotech company spun out from leading UK universities, specializing in advanced drug delivery through its proprietary Molecular Envelope Technology (MET) and METfect platforms. The company has successfully advanced its lead ophthalmology candidate, OC134, through a Phase I trial and has out-licensed a CNS-targeted analgesic, demonstrating clinical validation and partnership potential. With a focus on overcoming biological barriers for ocular, CNS, and gene therapies, Nanomerics leverages its deep academic roots and experienced leadership to repurpose and enhance known drugs, addressing significant unmet medical needs.

Molecular Envelope Technology (MET): A biocompatible polymer nanoparticle platform that forms a matrix (not a micelle) to package hydrophobic drugs and enhance delivery across epithelial barriers for ocular and CNS applications. METfect: A non-viral gene delivery extension of MET for intranasal administration of siRNA/pDNA to the brain.

Nanomerics competes in the crowded drug delivery and nanotechnology space, facing competition from other specialty biotechs (e.g., EyePoint Pharma in ophthalmology) and large pharma internal efforts. Its differentiation lies in the specific polymer matrix architecture of MET and the intranasal route for CNS/gene delivery, but it must continually innovate to maintain an edge against evolving technologies.